Longeveron Inc. · NASDAQ:LGVN
Longeveron — Q4 2025 Earnings Presentation
31 slides from Longeveron's earnings presentation, Mar 17, 2026
Slide 1: A Regenerative Medicine Company
A Regenerative Medicine Company Stem cell therapies addressing life threatening conditions in the most vulnerable populations - children and the elderly Investor Presentation Nasdaq (LGVN) │ March 2026
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and esti
Slide 3: Therapies for life-threatening, rare pediatric & chronic aging-related conditions
Therapies for life-threatening, rare pediatric & chronic aging-related conditions POSITIVE REGULATORY 5 FDA LARGE U.S. CLINICAL DATA PATHWAY TO BLAs DESIGNATIONS MARKETS ➢ Positive initial results in 5 ➢ Positive FDA Type C ➢ HLHS: Orphan Drug, HLHS: ~$1 billion clinical trials across 3 mtg for HLHS
Slide 4: Cellular Therapy Laromestrocel (Lomecel BTM) -- A Pipeline in a Product
Cellular Therapy Laromestrocel (Lomecel BTM) -- A Pipeline in a Product • Stem cell therapy uses stem cells to repair, regenerate or replace damaged or diseased cells in the body • Allogeneic (donor-derived) mesenchymal stem cells (MSCs) isolated from bone marrow of healthy young adults (18 to 45) •
Slide 5: Addressing Unmet Medical Needs of Chronic and Life-threatening Conditions
Addressing Unmet Medical Needs of Chronic and Life-threatening Conditions Hypoplastic Left Heart Pediatric Dilated Alzheimer’s Disease Aging-related Frailty Syndrome (HLHS) Cardiomyopathy (PDCM) (AD) (AF) • One of most severe • Pediatric cardiomyopathies affect • 1 in 3 older adults dies with • By 2
Slide 6: Lomecel-B (laromestrocel) -- A pipeline in a product
Lomecel-B® (laromestrocel) -- A pipeline in a product Global Patient Pivotal or Population Phase 1 Phase 2 Phase 3 Milestones • Ph2b enrollment completed, Top- Hypoplastic Left line data anticipated Q3 2026 > 30,0001 Heart Syndrome • Rare Pediatric Disease, Orphan Drug, Fast Track Designations • IND
Slide 7: Laromestrocel Multiple Mechanisms of Action (MOA)
Laromestrocel Multiple Mechanisms of Action (MOA) Pro-vascular, Pro-regenerative and Anti-inflammatory: Repairs Tissue and Promotes Healing Laromestrocel Anti-inflammatory Cell-cell Interactions Exosome and MicroRNA Mitochondrial Transfer Cytokines (stem cells) Release (somatic cells) Key Advantages
Slide 8: Laromestrocel Mechanism of Action
Laromestrocel Mechanism of Action Potential Mechanisms of Action These mechanisms support use in ▪ Diseases with endothelial ▪ Pro-vascular/pro-endothelial dysfunction ▪ Anti-inflammatory ▪ Inflammation ▪ Anti-fibrotic ▪ Fibrosis ▪ Stimulate intrinsic ▪ Need for endogenous repair regenerative/repair
Slide 9: Laromestrocel for Hypoplastic Left Heart Syndrome (HLHS)
Laromestrocel for Hypoplastic Left Heart Syndrome (HLHS)
Slide 10: Significant Unmet Need in HLHS
Significant Unmet Need in HLHS • Rare congenital heart defect: Univentricular malformation • Children with HLHS require 3 staged open- heart surgeries for survival • Even with surgery, survival to adolescence estimated at only 50% to 60%2 • 5 years transplant-free survival ~80%3,4 • Urgent need for
Slide 11: Lomecel-B is a therapy for HLHS to be administered during the stage II Glenn surgery
Lomecel-B® (laromestrocel) is a therapy for HLHS to be administered during the stage II Glenn surgery Lomecel-B® administered into • Administration via RV during stage II surgery intramyocardial injection has been clinically shown to Glenn (St II @ ~4 mos): redirects blood to PA enhance cell retenti
Slide 12: Long-term Survival Data Presented at 2024 Congenital Heart Surgeon's Society Annual Meeting
Long-term Survival Data Presented at 2024 Congenital Heart Surgeon’s Society Annual Meeting ELPIS I - 100% transplant-free survival for 10 patients up to 5 years post Glenn surgery • ELPIS I met its primary endpoint of safety through 1-year post-treatment, with 100% survival rate, 100% transplant-fr
Slide 13: Long-term Survival in HLHS from ELPIS I Trial of laromestrocel
Long-term Survival in HLHS from ELPIS I Trial of laromestrocel Post-Stage II Heart Transplant-Free 5-years Survival SVR patients matched with ELPIS I patient’s population (N=157) ELPIS I patient’s population (N=10) • 100% Transplant-free survival for all patients in ELPIS I, ranging from 3 years 8 m
Slide 14: ELPIS II: Pivotal Phase 2b Study Design for HLHS
ELPIS II: Pivotal Phase 2b Study Design for HLHS Injections During Stage II Surgery Post Surgical Follow-Up Clinical Screening Baseline (randomized, blinded) (day 5, week 4, month 6, month 12) N=20 Eligibility Criteria • Patient assessments Group 1 Key Measures Assessed All participants must have HL
Slide 15: ELPIS II Primary and Key Secondary Endpoints
ELPIS II Primary and Key Secondary Endpoints Composite Primary Endpoint Key Secondary Endpoint Time to all-cause mortality or listing for transplant at 12 months post • Incidence of major adverse cardiac events (MACE) from Stage II surgery (time to earliest event) baseline through Month 12 post Stag
Slide 16: Laromestrocel for Pediatric Dilated Cardiomyopathy (PDCM)
Laromestrocel for Pediatric Dilated Cardiomyopathy (PDCM)
Slide 17: Pediatric Dilated Cardiomyopathy (PDCM) - 2nd indication
Pediatric Dilated Cardiomyopathy (PDCM) - 2nd indication • Pediatric Dilated Cardiomyopathy (PDCM) is a rare, progressive, life-threatening disease • ~40% of children with dilated cardiomyopathy require a heart transplant or die within two years of diagnosis • Current treatment focuses only on manag
Slide 18: Lomecel-B (laromestrocel) for PDCM
Lomecel-B® (laromestrocel) for PDCM By reducing inflammation, inhibiting fibrosis, and promoting new blood vessel formation, Lomecel-B® may stop or reverse deterioration of heart function in PDCM. FDA supports an accelerated clinical Lomecel-B® development and regulatory pathway for Lomecel-B® to in
Slide 19: Laromestrocel for Alzheimer's Disease (AD)
Laromestrocel for Alzheimer’s Disease (AD)
Slide 20: Laromestrocel for Alzheimer's Disease
Laromestrocel for Alzheimer’s Disease Targeting CNS Inflammation • Previous therapies targeted amyloid plaques (b-secretase inhibitors and anti-amyloid antibodies) or neurofibrillary tangles (antibodies) with little evidence of disease state improvement • Inflammation is increasingly recognized as a
Slide 21: CLEAR MIND Phase 2a Study Design
CLEAR MIND Phase 2a Study Design Screening 4 X Infusions Final Follow Up Baseline Weeks -6 -4 0 4 8 12 16 26 39 Study Begins Randomization 1:1:1:1 Percentage of patients with at least Primary Endpoint 1 SAE 4 weeks from any infusion Group 1: Placebo [N=12] Group 2: Single Dose laromestrocel (25M) [N
Slide 22: CLEAR MIND Phase 2a Results for Alzheimer's Disease
CLEAR MIND Phase 2a Results for Alzheimer’s Disease ▪ Trial results selected for featured research oral presentation at the 2024 Alzheimer's Association International Conference (AAIC) July 2024 ▪ Laromestrocel demonstrated positive benefit/risk profile ▪ Laromestrocel treated patients showed an ove
Slide 23: CLEAR MIND Phase 2a Conclusions and Pathway to BLA
CLEAR MIND Phase 2a Conclusions and Pathway to BLA ▪ Results of the CLEAR MIND clinical trial support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer’s disease and provided evidence-based support for further clinical development ▪ Results of the CLEAR MIND Phase 2a clin
Slide 24: Laromestrocel for Aging-related Frailty (AF)
Laromestrocel for Aging-related Frailty (AF)
Slide 25: Aging-related Frailty
Aging-related Frailty* Diminishing Health, Independence and QoL • Frailty Etiology of Aging-related Frailty ‒ Age-associated decline in reserve and function across multiple physiologic systems leading to inability to cope with stressors ‒ Characterized by mobility disability, weakness, fatigue, weig
Slide 26: Laromestrocel for Aging-related Frailty
Laromestrocel for Aging-related Frailty Completed U.S. Phase 2b Study Aging-related Frailty Study (N=143) • Designed to determine whether there was a dose response to a single infusion of laromestrocel in Aging- Results: related Frailty There was a statistically significant increase in • There were
Slide 27: Financial Position
Financial Position $4.7 M ~23.3 M (as of 12/31/25) (as of 03/09/26) Cash and cash equivalents Shares of Class A and Class B common stock outstanding; ~$1.4 M ~21.9M shares of common stock (as of 12/31/25) exercisable under outstanding warrants, as of 12/31/2025 Working Capital In March 2026, the Com
Slide 28: Longeveron Priorities for Next Months
Longeveron Priorities for Next 12 Months • Type C meeting with FDA to prepare for data read-out of ELPIS II in HLHS • Conclude data read-out of the ELPIS II clinical trial in HLHS • Conduct HLHS pre-BLA meeting with FDA • Expand our focus on partnership identification and evaluation efforts across a
Slide 29: Experienced and Successful Leadership
Experienced and Successful Leadership Joshua Hare, MD Stephen Willard Lisa Locklear EXECUTIVE CHAIRMAN, EVP & CHIEF FINANCIAL CHIEF EXECUTIVE OFFICER CO-FOUNDER & OFFICER CHIEF SCIENCE OFFICER Paul Lehr Devin Blass Nataliya Agafonova, MD GENERAL COUNSEL & SECRETARY CHIEF MEDICAL OFFICER CTO & SVP, C
Slide 30: Therapies for life-threatening, rare pediatric & chronic aging-related conditions
Therapies for life-threatening, rare pediatric & chronic aging-related conditions POSITIVE REGULATORY 5 FDA LARGE U.S. CLINICAL DATA PATHWAY TO BLAs DESIGNATIONS MARKETS ➢ Positive initial results in 5 ➢ Positive FDA Type C ➢ HLHS: Orphan Drug, HLHS: ~$1 billion clinical trials across 3 mtg for HLHS
Slide 31: Thank You
Thank You Website www.longeveron.com Chief Financial Officer Lisa Locklear llocklear@longeveron.com Investor Relations Derek Cole Investor Relations Advisory Solutions derek.cole@IRadvisory.com Social Media Converge Miami 1951 NW 7th AVENUE Suite 520 @Longeveron Inc Miami, FL 33136 @LGVNSocial 844-4